News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Diabetes Drug Fails Head-to-head Against Victoza



11/16/2011 6:46:05 AM

GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like peptide-1 (GLP-1) agonist currently undergoing Phase III trials to help type II diabetes patients reduce their blood sugar levels after they have failed on oral treatments.



comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES